Compile Data Set for Download or QSAR
maximum 50k data
Found 1580 with Last Name = 'meibom' and Initial = 'd'
TargetAdenosine receptor A2b(Homo sapiens (Human))
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50086170((4-Cyano-phenyl)-carbamic acid 4-(2,6-dioxo-1,3-di...)
Affinity DataKi:  2nMAssay Description:Inhibition of human A2B adenosine receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin F2-alpha receptor(Homo sapiens (Human))
Bayer

Curated by ChEMBL
LigandPNGBDBM520995((+)-5-[({6-Bromo-3-methyl-2-[(2H8)pyrrolidin-1-yl]...)
Affinity DataKi:  16nMAssay Description:Displacement of [3H]PGF2alpha from full-length recombinant human FP receptor expressed in HEK293 cell membranes measured after 60 mins by scintillati...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAdenosine receptor A2b(Homo sapiens (Human))
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50336977(CHEMBL1672627 | N-[5-(3-Fluoropyridin-4-yl)-6-pyri...)
Affinity DataKi:  24nMAssay Description:Inhibition of human A2B adenosine receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAdenosine receptor A2a(Homo sapiens (Human))
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50531422(CHEMBL4522981)
Affinity DataKi: >1.00E+3nMAssay Description:Displacement of [3H]CGS21680 from human A2A adenosine receptor expressed in HEK293 cell membranes after 120 mins by radioligand displacement assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAdenosine receptor A1(Homo sapiens (Human))
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50531422(CHEMBL4522981)
Affinity DataKi: >1.00E+3nMAssay Description:Displacement of [3H]DPCPX from human A1 adenosine receptor expressed in CHO cell membranes after 60 mins by radioligand displacement assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAdenosine receptor A3(Homo sapiens (Human))
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50531422(CHEMBL4522981)
Affinity DataKi: >1.00E+4nMAssay Description:Displacement of [125I]AB-MECA from human A3 adenosine receptor expressed in HEK293 cell membranes after 120 mins by radioligand displacement assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetAdenosine receptor A2b(Homo sapiens (Human))
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM10849(1,3,7-trimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-d...)
Affinity DataKi:  1.00E+4nMAssay Description:Inhibition of human A2B adenosine receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413725(N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(1H-tetr...)
Affinity DataIC50:  0.260nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413625(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-metho...)
Affinity DataIC50:  0.260nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413725(N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(1H-tetr...)
Affinity DataIC50:  0.260nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413625(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-metho...)
Affinity DataIC50:  0.260nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM104820(US8569314, 5)
Affinity DataIC50: <0.300nMAssay Description:In vitro HNE inhibition assay. The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amido...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM104821(US8569314, 9)
Affinity DataIC50: <0.300nMAssay Description:In vitro HNE inhibition assay. The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amido...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM104822(US8569314, 23)
Affinity DataIC50: <0.300nMAssay Description:In vitro HNE inhibition assay. The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amido...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM104823(US8569314, 35)
Affinity DataIC50: <0.300nMAssay Description:In vitro HNE inhibition assay. The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amido...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM104824(US8569314, 50)
Affinity DataIC50: <0.300nMAssay Description:In vitro HNE inhibition assay. The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amido...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM104825(US8569314, 53)
Affinity DataIC50: <0.300nMAssay Description:In vitro HNE inhibition assay. The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amido...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM104826(US8569314, 56)
Affinity DataIC50: <0.300nMAssay Description:In vitro HNE inhibition assay. The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amido...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189812(US9174997, 10)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189813(US9174997, 12)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189814(US9174997, 14)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189815(US9174997, 18)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189818(US9174997, 27)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189819(US9174997, 32)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189820(US9174997, 33)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189821(US9174997, 36)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189822(US9174997, 41)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189823(US9174997, 43 (Diastereomer 1))
Affinity DataIC50:  0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189831(US9174997, 51)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189835(US9174997, 55)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189860(US9174997, 80)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189865(US9174997, 85)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189871(US9174997, 91)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189876(US9174997, 96)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189883(US9174997, 103)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189896(US9174997, 116)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189900(US9174997, 120)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189908(US9174997, 128)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189921(US9174997, 141)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeutrophil elastase(Homo sapiens (Human))
Bayer Intellectual Property

US Patent
LigandPNGBDBM189924(US9174997, 144)
Affinity DataIC50: <0.300nMpH: 7.4 T: 2°CAssay Description:The potency of the compounds of the invention is ascertained in an in vitro inhibition assay. The HNE-mediated amidolytic cleavage of a suitable pept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413721(4-{[(2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl...)
Affinity DataIC50:  0.310nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413721(4-{[(2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl...)
Affinity DataIC50:  0.310nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413727((2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-...)
Affinity DataIC50:  0.340nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413626(4-[(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50:  0.340nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413727((2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-...)
Affinity DataIC50:  0.340nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413626(4-[(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50:  0.340nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413719(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50:  0.360nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413745(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50:  0.360nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(4-[(2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-me...)
Affinity DataIC50:  0.360nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(4-[(2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-me...)
Affinity DataIC50:  0.360nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1580 total ) | Next | Last >>
Jump to: